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124Comparison of Short-Term Response and Long-Term
Outcomes after Initial Systemic Treatment of Chronic
Graft-Versus-Host Disease
Paul J. Martin,1,2 Barry E. Storer,1,3 Paul A. Carpenter,1,4 Daniel R. Couriel,5
Mary E. D. Flowers,1,2 Vikas Gupta,6 Jack W. Hsu,7 Madan Jagasia,8
Carrie L. Kitko,5 Richard T. Maziarz,9 Scott D. Rowley,10 Paul J. Shaughnessy,11
Koen van Besien,12 Daniel Weisdorf,13 Stephanie J. Lee1,2Clinical trials of chronic graft-versus-host disease (cGVHD) often use early endpoints, such as clinical
response at 3 or 6 months, as the primary endpoint instead of measures of long-term treatment success,
such as the ability to discontinue immunosuppressive treatment after development of immune tolerance
and resolution of active disease. We evaluated the ability of defined overall and organ-specific response cat-
egories at 3 and 6 months to predict the subsequent success or failure of primary treatment. The analysis
included 116 patients evaluated at 3 months after enrollment and 94 patients evaluated at 6 months after
enrollment. Success was defined as withdrawal of systemic treatment after resolution of cGVHD without
secondary therapy. Failure was defined as secondary systemic treatment, or death or development of bron-
chiolitis obliterans during primary treatment.With most definitions, response at 3 months and response at 6
months were not statistically significantly correlated with subsequent success of primary treatment. With
some definitions, the absence of response at 6 months had a statistically significant correlation with subse-
quent failure of primary treatment. These findings suggest that early response to the agents currently used
for primary treatment does not necessarily predict subsequent tolerance, an important endpoint in the
management of cGVHD. Rigorously defined clinical response is an appropriate primary endpoint for studies
of cGVHD, but future clinical trials should provide for extended follow-up to ascertain late outcomes that are
not necessarily predictable by evaluation of response before 6 months.
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II studies [2]. Progress in the field would be greatly
aided by development of a validated shorter-term
endpoint that could be used in future clinical trials to
evaluate new approaches for treatment of cGVHD.
Data from a randomized, multicenter, blinded
phase III trial testing mycophenolate mofetil (MMF)
added to initial systemic treatment of cGVHD pro-
vided an opportunity to validate early endpoints as
correlates of subsequent treatment outcomes [3]. Stan-
dardized assessments of organ-specific and overall re-
sponses, as well as medication doses, were performed
every 3 months. Withdrawal of all systemic treatment
after resolution of reversible disease manifestations
without secondary systemic treatment was selected as
the primary endpoint for the clinical trial, because
this outcome represents cure of GVHD as the in-
tended final goal of cGVHD treatment. The trial
was stopped prematurely because an interim analysis
suggested no improvement in outcome after the addi-
tion of MMF to initial treatment.
In the current analysis, we hypothesized that amajor
improvement in the manifestations of cGVHD was as-
sociated with subsequent early resolution of cGVHD
and withdrawal of all immunosuppressive treatment
without the need for secondary systemic treatment. A
strong correlation between initial response and subse-
quent success for the primary endpoint in this study
would support the use of initial response as a surrogate
for subsequent success of primary treatment for
cGVHD in future clinical trials.PATIENTS AND METHODS
Patients
Figure 1 illustrates the flow of patients in the origi-
nal study [3]. The current analysis focused on the 116
patients who had responses evaluated after 3 months
and on the 94 patients who had responses evaluated
after 6 months. The median follow-up of the patients
evaluated after 3 months was 21.9 months (range, 3.2-
49.0 months), and that of the patients evaluated after 6
months was 22.9 months (range, 6.4-49.0 months). In-
formed consent by each participant was documented
with the use of forms approved by the Institutional Re-
viewBoards of FredHutchinsonCancerResearchCen-
ter and the participating transplantation centers, in
accordance with the Declaration of Helsinki.Definitions of Early Responses
At enrollment and at 3-month intervals thereafter,
physicians evaluated GVHD manifestations involving
the skin, mouth, eyes, gastrointestinal tract, joints,
genitalia, and liver according to a 4-point scale ofdisability, similar to the scoring categories proposed
by the National Institutes of Health (NIH) Consensus
Development Project on Criteria for Clinical Trials in
Chronic Graft-versus-Host Disease [4]. On this scale,
a score of 0 indicates the absence of active disease
manifestations, a score of 1 indicates abnormalities
associated with no more than mild disability, a score of
2 indicatesmoderate disability, and a score of 3 indicates
severe disability. Myositis, esophageal involvement,
eosinophilia, and thrombocytopenia (platelet count
\100,000/mL)were recorded as absent or present. Enu-
meration of cGVHD manifestations or involved sites
included myositis, esophagus, and eosinophilia, but
not thrombocytopenia. Physicians were asked to grade
the overall clinical severity of cGVHD as absent,
mild, moderate, or severe, without specific definitions.
Changes in severitywere used to infer the physicians’ as-
sessment of response. Physicianswere also asked to eval-
uate changes in overall severity from one quarterly
assessment to the next, without specific definitions, but
were not asked directly to specify a response category.
Overall severity also was calculated retrospectively ac-
cording to the algorithm proposed by theNIHConsen-
sus Development Project [4]. At baseline and at
quarterly intervals thereafter, patients completed aques-
tionnaire that included the chronic GVHD Symptom
Scale, which measures the extent to which patients
were bothered by manifestations of cGVHD [5].
Clinical manifestations of cGVHD assessed on the
4-point scale were considered as improved if the score
at the response evaluation was lower than the baseline
score by at least 1 point, and manifestations were con-
sidered worse if the score was higher than the baseline
score by at least 1 point. Manifestations assessed as
present or absent were scored as improved if an abnor-
mality seen at baseline was absent at the response eval-
uation and as worse if an abnormality at the response
evaluation was absent at baseline. Changes in eosino-
philia and thrombocytopenia were not considered
when evaluating changes between baseline and the re-
sponse evaluation. PR was defined as improvement in
at least one organ without worsening in other organs.
CR was defined as a score of 0 in all organs. These cri-
teria for PR are less stringent than those proposed by
the Response Criteria Working Group Report of the
NIHConsensus Development Project [6]. Data report
forms for the trial were designed before the NIHCon-
sensus Development Project on Criteria for Clinical
Trials in Chronic GVHD [4,6]; for this reason, we
were not able to determine responses precisely
according to criteria proposed in the Response
Criteria Working Group Report.
cGVHD symptom scores were considered im-
proved if the summary score at 3 or 6 months was $7
points lower than thebaseline score andwere considered
worsened if the score at the response evaluation was$7
points higher than the baseline score. A 7-point change
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Figure 1. Flow diagram showing outcomes of primary treatment before and after 3 and 6 months from enrollment in the study.
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score at baseline among participants in this study,
similar to the original study of Lee et al. [5].Definitions of Success and Failure of Primary
Treatment
In this study, success of primary treatment was
defined aswithdrawal of all systemic treatment after res-
olution of reversiblemanifestations of cGVHD,with no
secondary systemic treatment, regardless of time from
enrollment.The 2-year time limit used to define success
in the original study [3] was not applied in the present
study. Withdrawal of treatment to improve donor
chimerism or to induce an antitumor response after
recurrent or secondary malignancy was not considered
a success. Failure of primary treatment was defined asthe initiation of secondary systemic treatment, nonre-
lapse death, or development of bronchiolitis obliterans
during primary treatment.
Secondary systemic treatment included any inter-
vention intended to control cGVHD through the use
of any systemic agent that was not included in the pri-
mary treatment regimen. Administration of systemic
glucocorticoids to patients who were not treated ini-
tially with glucocorticoids was considered secondary
systemic treatment. Topical agents were not considered
secondary systemic treatment. An increase in the dose of
prednisone and any resumption of treatment with pred-
nisone or the study drug after previous discontinuation
for any reason was not considered secondary systemic
treatment. Any increase in the dose of cyclosporine
(CsA) or tacrolimus or resumption of treatment with
CsA or tacrolimus after previous discontinuation for
Biol Blood Marrow Transplant 17:124-132, 2011 127Endpoints in Chronic GVHD Studiesany reasonwas not considered secondary systemic treat-
ment if the drug in question was included in the primary
treatment regimen. A change in treatment from CsA to
tacrolimus or vice versa resulting from drug toxicity was
not considered secondary treatment, but any such
change made because of uncontrolled cGVHD was
considered secondary treatment. Patients who were still
receiving primary treatment when the trial was termi-
natedwere not evaluated for the success or failure of pri-
mary treatment, because neither endpoint was reached.
Statistical Analysis
The results of the original study demonstrated no
measurable benefit whenMMFwas added to the initial
systemic treatment for cGVHD[3]. For this reason, the
current analysis did not include consideration of
whether or not patients received MMF. The cumula-
tive incidence of success or failure of primary treatment
and the associated standard error were estimated as
described previously [7]. Cox proportional hazards
models were used to evaluate the association of re-
sponse categories and characteristics at 3 and 6 months
with subsequent success or failure of primary treat-
ment. In these models, recurrent malignancy during
primary treatment was treated as a competing risk,
and follow-up was censored for patients who were still
receiving primary treatment when the study ended.RESULTS
Testing of A Priori Response Definitions
Nine a priori definitions of clinical responses at
3 and 6monthswere initially tested for their associationTable 1. A Priori Response Definitions Tested at 3 Months for Corre
(n 5 116)
Response Definition
3-Month
Response n
Improved in any organ Yes 108
No 8
Improved or stable in all organs Yes 84
No 32
Improved in all organs Yes 40
No 76
CR in any organ Yes 102
No 14
CR in any organ, all others stable or improved Yes 74
No 42
Overall PR or CR Yes 79
No 37
Overall CR Yes 27
No 89
GVHD symptom score unchanged or improved‡ Yes 92
No 16
GVHD symptom score improved‡ Yes 38
No 70
CR indicates complete response; GVHD, graft-versus-host disease.
*At 2 years 6 standard error.
†Derived from the Cox model.
‡The total of “yes” and “no” is less than 116 because of missing data.with subsequent success or failure of primary treat-
ment: improvement in any organ, improvement or
no change in all organs, improvement in all organs,
CR in any organ, CR in any organ with improvement
or stability in all other organs, overall PR or CR, over-
all CR, stable or improved cGVHD symptom score,
and improved GVHD symptom score. In the original
study [3], nearly all patients had success or failure of
primary treatment or a competing risk within 2 years
after enrollment. In the present analysis, the 116 pa-
tients evaluated at 3 months and the 94 evaluated at
6 months after enrollment had a respective cumulative
incidence rate of subsequent success of primary ther-
apy of 25% and 28% at 2 years. Based on these results,
response at 3 or 6 months according to a useful defini-
tion should predict a substantially greater than 25%-
28% cumulative incidence of subsequent success at 2
years. The corresponding cumulative incidence rates
of subsequent failure of primary therapy were 49%
and 47% at 2 years. Thus, the absence of response
according to a useful definition should predict a sub-
stantially greater than 47%-49% cumulative incidence
of subsequent failure at 2 years.
Table 1 lists the 9 a priori response definitions,
subdivided according to whether or not the response
was attained at 3 months. The cumulative incidence
of subsequent success at 2 years associated with re-
sponse according to the 9 a priori definitions ranged
from 22% to 34%, not substantially higher than the
25% overall success rate seen for the entire group
of 116 patients without consideration of response.
Response defined as a stable or improved cGVHD
symptom score at 3 months and response defined as
improvement in any organ at 3 months werelation with Subsequent Success or Failure of Primary Therapy
Cumulative Incidence
of Success* P†
Cumulative Incidence
of Failure* P†
26 ± 5 .03 48 ± 6 .23
0 100
25 ± 6 .23 43 ± 7 .16
28 ± 9 60 ± 10
22 ± 8 .94 29 ± 9 .08
26 ± 6 58 ± 7
27 ± 5 .14 49 ± 6 .15
9 ± 8 48 ± 20
27 ± 6 .97 44 ± 7 .77
21 ± 7 58 ± 10
25 ± 6 .63 44 ± 7 .56
24 ± 8 63 ± 10
26 ± 10 .50 30 ± 10 .27
25 ± 6 54 ± 7
30 ± 6 .01 44 ± 6 .08
0 72 ± 14
34 ± 9 .90 45 ± 10 .48
22 ± 6 48 ± 7
Table 2. A Priori Response Definitions Tested at 6 Months for Correlation with Subsequent Success or Failure of Primary Therapy
(n 5 94)
Response Definition
6-Month
Response n
Cumulative Incidence
of Success* P†
Cumulative Incidence
of Failure* P†
Improved in any organ Yes 89 30 ± 6 .11 43 ± 6 .19
No 5 0 100
Improved or stable in all organs Yes 61 29 ± 7 .87 37 ± 8 .01
No 33 26 ± 9 63 ± 10
Improved in all organs Yes 28 27 ± 10 .78 39 ± 12 .12
No 66 28 ± 7 51 ± 7
CR in any organ Yes 80 30 ± 6 .55 41 ± 7 .22
No 14 16 ± 11 73 ± 13
CR in any organ, all others stable or improved Yes 58 30 ± 7 .98 36 ± 8 .008
No 36 25 ± 8 64 ± 10
Overall PR or CR Yes 61 29 ± 7 .87 37 ± 8 .01
No 33 26 ± 9 63 ± 10
Overall CR Yes 22 33 ± 11 .36 42 ± 13 .22
No 72 26 ± 6 49 ± 7
GVHD symptom score unchanged or improved‡ Yes 75 28 ± 6 .77 43 ± 7 .07
No 11 21 ± 13 68 ± 15
GVHD symptom score improved‡ Yes 31 38 ± 10 .54 45 ± 11 .79
No 55 21 ± 6 47 ± 8
CR indicates complete response; PR, partial response; GVHD, graft-versus-host disease.
*At 2 years 6 standard error.
†Derived from the Cox model.
‡The total of “yes” and “no” is less than 94 because of missing data.
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the absence of response by these definitions (P 5
.01 and .03, respectively). With one exception, the
cumulative incidence of subsequent failure at 2 years
associated with the absence of response at 3 months
according to the 9 a priori definitions ranged from
48% to 72%. All 8 patients with absence of improve-
ment in any organ at 3 months had subsequent failure
of primary treatment. None of the a priori response
definitions evaluated at 3 months showed a statisti-
cally significant association with subsequent failure
of primary treatment.
Table 2 shows results for the 9 a priori response
definitions tested at 6 months. The cumulative inci-
dence of subsequent success at 2 years associated
with response according to these definitions ranged
from 27% to 38%, again not substantially greater
than the 28% overall success rate for the entire group
of 94 patients. None of the a priori response defini-
tions evaluated at 6 months showed a statistically
significant association with subsequent success of pri-
mary treatment. With one exception, the cumulative
incidence of subsequent failure at 2 years associated
with the absence of response at 6 months according
to the 9 a priori definitions ranged from 47% to
73%. All 5 patients with absence of improvement in
any organ at 6 months had subsequent failure of pri-
mary treatment. The absence of response defined as
improvement or stability in all organs, CR in any organ
with all other organs stable or improved, and overall
PR or CR at 6 months showed a statistically significant
association with subsequent failure of primary treat-
ment (P 5 .01, .008, and .01, respectively).Differences between Groups Defined According
to Success and Failure of Primary Treatment
Because the a priori definitions of overall response
at 3 or 6 months generally did not predict subsequent
success of primary treatment, we embarked on an ex-
ploratory search for other measures at 3 and 6 months
that might predict subsequent success or failure of
primary treatment. This search identified a few mea-
sures that differed between patients with subsequent
treatment success and those with subsequent treat-
ment failure. At 3 months, gastrointestinal tract scores
were lower and platelet counts were higher in patients
with subsequent success compared with those with
subsequent failure (data not shown). At 6 months, liver
scores, overall severity scores assigned by physicians,
and prednisone-equivalent glucocorticoid doses were
lower in patients with subsequent success (mean 6
SD, 0.06 6 0.10 mg/kg/day) compared with those
with subsequent failure (0.176 0.19 mg/kg/day). Glu-
cocorticoid doses were not available at 6 months for 4
patients, 2 with subsequent success and 2 with subse-
quent failure. Twenty of the 21 patients with treatment
success (95%) had a prednisone-equivalent glucocorti-
coid dose \0.25 mg/kg/day at 6 months, compared
with 21 of 30 patients with treatment failure (70%).
Our exhaustive examination revealed no statistically
significant differences in change from baseline to 3
months between patients with subsequent success and
those with subsequent failure (data not shown). We
found only one statistically significant difference in
change from baseline to 6 months between patients
in the two groups. All 5 patients with joint involvement
in the success group showed improvement at 6 months,
Biol Blood Marrow Transplant 17:124-132, 2011 129Endpoints in Chronic GVHD Studiescompared with only 1 of 6 patients with joint involve-
ment in the failure group.
Testing of Additional Response Definitions
Because gastrointestinal disease and thrombocyto-
penia at 3 months were identified as potentially impor-
tant additional predictive variables, we evaluated the
association between thesemeasures and subsequent suc-
cess or failure of primary treatment. In this analysis, the
absence of gastrointestinal manifestations and the ab-
sence of thrombocytopenia (platelet count\100,000/
mL) at 3 months had no statistically significant associa-
tion with subsequent success of primary treatment
(data not shown). Likewise, the presence of thrombocy-
topenia at 3 months was not associated with subsequent
failure of primary treatment; however, the presence of
gastrointestinal manifestations at 3 months did show
a statistically significant association with subsequent
failure of primary treatment (P5 .008).
Prednisone-equivalent glucocorticoid dose\0.25
mg/kg/day at 6 months was added as a criterion for
each of the a priori response definitions tested for
association with subsequent outcome. Response
definitions for this analysis also included a liver score
of 0 and a physician severity score of 0 or 1 at 6 monthsTable 3. Modified ResponseDefinitions Tested at 6Months for Corr
(n 5 94)
Modified Response Definition
6-Month
Response* n
Prednisone dose <0.25 mg/kg/day Yes 74
No 15
Improved in any organ§ Yes 71
No 18
Improved or stable in all organs§ Yes 50
No 39
Improved in all organs§ Yes 23
No 66
CR in any organ§ Yes 62
No 27
CR in any organ, all others stable or improved§ Yes 47
No 42
Overall PR or CR§ Yes 50
No 39
Overall CR§ Yes 19
No 70
GVHD symptom score unchanged or improved§ Yes 64
No 22
GVHD symptom score improved§ Yes 26
No 60
Liver score 0 Yes 67
No 27
Liver score 0§ Yes 53
No 36
Physician score 0 or 1 Yes 79
No 11
Physician score 0 or 1§ Yes 65
No 21
CR indicates complete response; PR, partial response; GVHD, graft-versus-ho
*The total of “yes” and “no” in most categories is <94 because of missing dat
†At 2 years 6 standard error.
‡Derived from the Cox model.
§With prednisone dose <0.25 mg/kg/day.with or without the additional criterion of prednisone-
equivalent glucocorticoid dose\0.25 mg/kg/day. The
results given in Table 3 show a cumulative incidence of
subsequent success at 2 years after a response at 6
months by these definitions ranging from 28% to
45%. A liver score of 0 with or without a predni-
sone-equivalent glucocorticoid dose \0.25 mg/kg/
day showed a statistically significant association with
subsequent success (P 5 .002 and .003, respectively).
By all other definitions, response at 6 months showed
no statistically significant association with subsequent
success. The cumulative incidence of subsequent fail-
ure at 2 years associated with the absence of response
at 6 months for these definitions ranged from 50%
to 84%. The absence of response by 9 definitions
at 6 months showed a statistically significant associa-
tion with subsequent failure, including the absence
of prednisone-equivalent glucocorticoid dose \0.25
mg/kg/day, and composite responses of improvement
in any organ, improvement or stability in all organs,
CR in any organ, CR in any organ with stability or
improvement in all others, overall CR or PR, and
unchanged or improved GVHD symptom score, to-
gether with a prednisone-equivalent glucocorticoid
dose \0.25 mg/kg/day. A physician severity scoreelationwith Subsequent Success or Failure of Primary Therapy
Cumulative Incidence
of Success† P‡
Cumulative Incidence
of Failure† P‡
30 ± 6 .25 39 ± 7 .04
9 ± 9 80 ± 12
31 ± 6 .17 37 ± 7 .009
7 ± 7 84 ± 10
30 ± 8 .84 33 ± 8 .009
24 ± 8 63 ± 9
28 ± 11 .55 38 ± 13 .26
26 ± 6 50 ± 7
32 ± 7 .41 34 ± 7 .008
15 ± 8 74 ± 10
30 ± 8 .70 31 ± 8 .006
23 ± 8 64 ± 9
30 ± 8 .84 33 ± 8 .009
24 ± 8 63 ± 9
34 ± 12 .27 38 ± 14 .32
25 ± 6 50 ± 7
31 ± 7 .75 37 ± 7 .02
18 ± 9 70 ± 11
45 ± 11 .33 36 ± 11 .37
20 ± 6 50 ± 8
39 ± 7 .003 43 ± 8 .26
4 ± 4 56 ± 11
41 ± 8 .002 36 ± 8 .16
6 ± 4 61 ± 10
28 ± 6 .83 40 ± 7 .001
18 ± 12 82 ± 12
29 ± 7 .71 34 ± 7 .004
18 ± 9 76 ± 11
st disease.
a.
130 Biol Blood Marrow Transplant 17:124-132, 2011P. J. Martin et al..1 at 6 months showed strong association with
subsequent failure, with or without including the
prednisone-equivalent glucocorticoid dose as a crite-
rion (P 5 .004 and .001, respectively).DISCUSSION
The results of the present study do not support our
hypothesis that major improvement in the manifesta-
tions of cGVHD is associated with subsequent early
resolution of cGVHD and withdrawal of all immuno-
suppressive treatment without the need for secondary
systemic treatment. With most definitions, clinical re-
sponse at 3 and 6 months did not predict the success of
primary treatment for cGVHD. In contrast, failure of
primary treatment for cGVHD could be predicted
according to the absence of clinical response by various
measures at 6 months, but not at 3 months. Most
patients demonstrated clinical improvement from
baseline to the response evaluations at 3 and 6 months
and were able to taper systemic steroid treatment
rapidly during the first 6 months regardless of subse-
quent failure or success of primary treatment, although
systemic glucocorticoid doses were lower at 6 months
in patients with subsequent treatment success com-
pared with those with subsequent treatment failure.
The management of cGVHD has the important
goals of relieving symptoms, preventing disability and
death, and developing immunologic tolerance, as indi-
cated by resolution of the cGVHD and permanent
withdrawal of systemic treatment without exacerbation
of residual disease manifestations [1,8]. The high
proportion of patients exhibiting clinical improvement
during the first 3-6 months after starting treatment
suggests that systemic glucocorticoids and calcineurin
inhibitors provide effective relief of symptoms. Studies
conducted in the early 1980s further indicated that in
most patients, early intervention with glucocorticoids
and calcineurin inhibitors prevents severe disability
that would otherwise be caused by cGVHD [8,9].
Previous studies have shown correlations between
certain baseline characteristics and a prolonged total
duration of systemic treatment for cGVHD before
the development of tolerance. The current study ana-
lyzed outcomes of primary treatment as opposed to
total duration of treatment, because the objective was
to define a short-term response measure that can be
used to indicate whether primary treatment might in-
duce immune tolerance in future clinical trials.This ap-
proach was based on the notion that when primary
treatment is successful, the total duration of treatment
is likely to be shorter, and when primary treatment fails
to induce tolerance, the total duration of treatment is
likely to be prolonged. Withdrawal of all systemic
treatment without a subsequent flare of cGVHDman-
ifestations serves as a robust functional test indicating
that the disease has been cured, an important goal oftreatment. On the other hand, it can be argued that
this definition of success is too stringent. In some cases,
manifestations of cGVHD can be controlled by trivial
doses of prednisone as a single treatment agent. In the
present study, we did not attempt to identify such cases
to assess whether our conclusions might change if we
used a less stringent definition of success. Likewise,
we did not evaluate whether response at 3 or 6 months
was associated with prevention of disability, another
important goal in the management of cGVHD.
The general absence of correlation between initial
clinical response and subsequent success of primary
treatment and development of tolerance in the present
study suggests that these outcomes are not functionally
linked with one another in patients treated with current
regimens of glucocorticoids, calcineurin inhibitors, and
MMF.These results suggest that agents thathavepotent
effects on relief of symptoms or prevention of disability
do not necessarily have an effect on the development
of immune tolerance. Relief of symptoms and preven-
tion of disability are likely to reflect the potent anti-
inflammatory effect of glucocorticoids, as well as the
immunosuppressive effects of other medications used
to treat GVHD. Development of tolerance after
hematopoietic cell transplantation presumably occurs
through clonal deletion, development of anergy or
nonresponsiveness, or emergence of T regulatory cells
[10,11], processes that are not necessarily facilitated by
glucocorticoids and calcineurin inhibitors or by MMF
in patients with cGVHD.
The strong association between an absence of liver
involvement at 6 months and subsequent success of
primary treatment is highly plausible, given that previ-
ous studies have shown that hyperbilirubinemia at the
onset of cGVHD is associated with prolonged dura-
tion of systemic treatment [2]. The strong association
of a physician severity score .1 at 6 months with sub-
sequent failure of primary treatment is also highly
plausible, given that physicians would be expected to
change systemic treatment when they perceive patients
to have a high burden of persistent disease manifesta-
tions after an adequate trial of initial treatment. For
future clinical trials, however, response measures that
predict the success of primary treatment would be far
more useful than response measures that predict
failure.
The present study has several limitations. First,
recurrent malignancy and closure of the trial at
a time when approximately one-third of the patients
were still receiving primary treatment limited the
number of informative success and failure events and
decreased the statistical power to observe associations
between initial response and subsequent outcomes.
Point estimates for the hazard ratio of success with cer-
tain response definitions ranged from 2.5 to 4.0, but
confidence intervals were wide, making it difficult to
draw firm conclusions. Although these observations
Biol Blood Marrow Transplant 17:124-132, 2011 131Endpoints in Chronic GVHD Studiesindicate a lack of robust power in these analyses, we
also note that clinical trials in cGVHD often enroll
fewer than 100 patients, which would impose similar
limitations. In retrospect, it would have been helpful
had the original study allowed longer follow-up to as-
certain late outcomes. Collection of these data at this
time would require reopening the study at each center.
Second, because the present exploratory study in-
volved multiple comparisons, statistically significant
differences at the .05 level should be interpreted with
caution. Third, our results might not be generally rep-
resentative of patients with cGVHD, given that\20%
of all patients diagnosed with cGVHD at our center
were enrolled in the study. Fourth, we were unable
to assess associations between early response and sub-
sequent survival, because the small number of deaths
did not provide adequate statistical power. At least
one previous study has shown a correlation between
response at 6 months and subsequent survival [12].
Responses in the present study were not catego-
rized according to NIH criteria, because the clinical
trial predated the NIH Consensus Development
Project [6]. It is noteworthy, however, that none of
the response definitions ranging across an entire
spectrum, from the minimally stringent category of
“improvement in at least one organ” to the maximally
stringent category of “overall CR” at 6 months,
showed a statistically significant correlation with sub-
sequent success of primary therapy. For this reason,
we believe that results with the NIH response criteria
also would have shown no statistically significant cor-
relation with subsequent success of primary therapy in
our study. The absence of statistically significant cor-
relations between early response and later outcome
could reflect limitations with the numbers of patients
or the types of treatment provided. This negative re-
sult does not rule out the possibility that statistically
significant correlations between early response and
later outcome might be found in future studies using
better methods for measuring response with larger
numbers of patients, with other types of treatment,
or with secondary treatment.
Our results have several broad implications for fu-
ture studies. First, because early response does not
necessarily correlate with early development of toler-
ance, response should be defined in a way that clearly
shows a demonstrable intrinsic clinical benefit, espe-
cially in trials where response is the primary endpoint.
Recommendations for measuring response suggested
by the NIH Consensus Development Project were de-
veloped as one approach toward achieving this goal [6].
An ideal treatment should reduce the burden of disease
manifestations to an acceptable minimum and prevent
disability without relying on continued treatment with
glucocorticoids or other immunosuppressive agents at
toxic doses [2]. Although disease manifestations at 6
months were similar in the success and failure groups,glucocorticoid doses were much higher in the failure
group. Clinical responses that can be sustained with
low doses of immunosuppressive treatment have
greater clinical significance than those that can be sus-
tained only with high doses of immunosuppressive
treatment and their associated increased risks of
opportunistic infection and long-term toxicity. For
this reason, clinical trials specifying response as the
primary endpoint should account for the amount of
glucocorticoid treatment, or possibly the cumulative
total amount of glucocorticoid treatment, as well as
changes from baseline in the burden of active disease
manifestations at a specified time point after enroll-
ment. Because steroid dose is under the physician’s
control, the validity of studies that incorporate steroid
dose in the assessment of response would be enhanced
by the use of blinded designs whenever feasible.
A second implication of our findings is that future
clinical trials should provide for extended follow-up to
ascertain late outcomes. CR or unequivocal PR within
6 months and a major reduction in the dose of gluco-
corticoids or other agents likely to cause long-term
toxicity provide significant real-time clinical benefits
to patients with cGVHD. Such responses also are
likely to be associated with a greatly reduced risk of
disability associated with the disease. At the same
time, however, cure of disease represents the ultimate
goal of treatment, even if it cannot serve as the primary
endpoint for most studies. Extended follow-up in
future studies is needed, because it cannot be assumed
that response before 6 months can accurately predict
subsequent cure of cGVHD. According to previous
results [3], follow-up for 2 years should suffice to assess
the success or failure of primary treatment in most
patients.
A third implication is that future studies should
focus on agents that might accelerate the development
of tolerance, in addition to controlling disease manifes-
tations. The current study, sponsored by the Clinical
Trials Network testing extracorporeal photopheresis
and sirolimus for treatment of high-risk or steroid-
dependent cGVHD, has been designed with this
goal in mind. Extracorporeal photopheresis might
accelerate the development of tolerance by increasing
the number or activity of T regulatory cells [13-16],
whereas treatment with sirolimus in the absence
of a calcineurin inhibitor might control T effector
cells without affecting the number or function of
T regulatory cells [17-20]. The primary endpoint of
the phase II component of this study will assess overall
CR or PR at 6 months after enrollment, and the
primary endpoint of the phase III component will
assess overall durable CR at 2 years after enrollment. A
more important difference in outcomes between arms
might emerge in the development of immune
tolerance as indicated by earlier withdrawal of systemic
treatment after resolution of cGVHDmanifestations.
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